| Compound Information | SONAR Target prediction |
| Name: | Diphenylpyraline hydrochloride |
| Unique Identifier: | Prest969 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | C19ClH24NO |
| Molecular Weight: | 293.662 g/mol |
| X log p: | 21.016 (online calculus) |
| Lipinksi Failures | 1 |
| TPSA | 12.47 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 2 |
| Rotatable Bond Count: | 4 |
| Canonical Smiles: | Cl.CN1CCC(CC1)OC(c1ccccc1)c1ccccc1 |
| Generic_name: | Diphenylpyraline |
| Chemical_iupac_name: | 4-benzhydryloxy-1-methyl-piperidine |
| Drug_type: | Approved Drug |
| Drugbank_id: | APRD00719 |
| Logp: | 4.325 |
| Cas_registry_number: | 147-20-6 |
| Drug_category: | Antihistamines; ATC:R06AA07 |
| Indication: | For use in the treatment of allergic rhinitis, hay fever, and allergic skin
disorders. |
| Pharmacology: | Diphenylpyraline is an antihistamine that prevents, but does not reverse, responses
mediated by histamine alone. Diphenylpyraline antagonizes most of the
pharmacological effects of histamine, including urticaria and pruritus. Also,
diphenylpyraline may exhibit anticholinergic actions (as do most of the
antihistamines) and may thus provide a drying effect on the nasal mucosa. |
| Mechanism_of_action: | Antihistamines such as diphenylpyraline used in the treatment of allergy act by
competing with histamine for H1-receptor sites on effector cells. This reduces the
effects of histamine, leading to a temporary reduction of allergy symptoms. |
| Organisms_affected: | Humans and other mammals |
